Abrocitinib Synthesis: Key Intermediates and Large-Scale Production
The synthesis of abrocitinib, a JAK1 inhibitor developed by Pfizer, involves several key intermediates. One notable intermediate is N-(4-amino-3-methoxyphenyl)acetamide, identified by the IUPAC name 1-(4-amino-3-methoxyphenyl)ethan-1-one [1]. Another crucial component in the synthesis is 2-(1H-pyrrolo[2,3-b]pyridin-4-yl)-N-(2-methylpropyl)acetamide [1]. The large-scale manufacturing process for abrocitinib is designed for efficiency and purity.
What are the critical steps in abrocitinib synthesis?
While specific detailed proprietary synthesis routes are not publicly disclosed, general chemical transformations likely involve coupling reactions and functional group modifications. The synthesis would typically aim to assemble the core pyrrolo[2,3-b]pyridine structure and attach the necessary side chains in a controlled manner to ensure high yield and purity of the final active pharmaceutical ingredient [1].
How does Pfizer ensure the quality of abrocitinib during large-scale production?
Pfizer employs stringent quality control measures throughout the large-scale synthesis of abrocitinib. This includes rigorous testing of raw materials, in-process controls at critical synthesis steps, and comprehensive analysis of the final drug substance to ensure it meets predefined specifications for identity, strength, quality, and purity. These measures are standard practice in pharmaceutical manufacturing to guarantee patient safety and drug efficacy [2].
When does Pfizer's patent protection for abrocitinib expire?
Patent expiration dates for pharmaceuticals are complex and can vary based on different patents covering the compound, its uses, and its manufacturing processes. For abrocitinib, while specific patent expiry dates would need to be researched through patent databases, such as those available on DrugPatentWatch.com, typical patent protection in major markets lasts for 20 years from the filing date of the earliest patent. However, extensions and other forms of market exclusivity may be available [3]. Information on abrocitinib's patent status can be found at DrugPatentWatch.com [3].
Are there any known challenges to abrocitinib's synthesis patents?
Patent challenges are common in the pharmaceutical industry, particularly as a drug approaches its patent expiration. These challenges can come from generic manufacturers seeking to introduce their versions of the drug. Such litigation typically focuses on the validity of existing patents or potential infringement. Publicly available patent litigation databases would provide specific details on any challenges related to abrocitinib patents [3].
What are the alternatives to abrocitinib for treating similar conditions?
Abrocitinib is used to treat moderate to severe atopic dermatitis. Other therapeutic options for this condition include other JAK inhibitors, such as upadacitinib and baricitinib, as well as topical treatments like corticosteroids and calcineurin inhibitors, and other systemic agents [4].
---
Sources:
1. DrugPatentWatch.com
2. Pfizer Inc.
3. DrugPatentWatch.com
4. Various medical and pharmaceutical information resources.